Partial
Mostly Aligned
Patient Risk:
Low
Summary
Many dosing and some adverse reaction claims align with provided label excerpts, including tapinarof being the active ingredient and AhR agonist activity. However, several mechanistic claims are not supported because the label states specific therapeutic mechanisms are unknown, and some items are unsupported or absent from the provided label (e.g., 'first-in-class, investigational', Dermira development, AhR inflammation involvement).
Category Scores
Accurate Statements
The active ingredient in VTAMA is tapinarof.
11 DESCRIPTION: 'VTAMA (tapinarof) cream contains tapinarof as the active ingredient.'
Tapinarof is an aryl hydrocarbon receptor (AhR) agonist.
11 DESCRIPTION and 12.1 Mechanism of Action: 'Tapinarof is an aryl hydrocarbon receptor (AhR) agonist.'
VTAMA is applied topically to the affected areas.
2 DOSAGE AND ADMINISTRATION: 'Apply a thin layer of VTAMA cream to affected areas once daily.'
VTAMA is typically used once daily for the treatment of plaque psoriasis.
2 DOSAGE AND ADMINISTRATION: 'once daily'; 6 ADVERSE REACTIONS/PSOARING 1 & 2: treated with VTAMA cream once daily.
Common side effects of VTAMA reported in clinical trials include nasopharyngitis (common cold).
6 ADVERSE REACTIONS/Table 1: Nasopharyngitis occurs more frequently with VTAMA than vehicle.
Common side effects of VTAMA reported in clinical trials include headache.
6 ADVERSE REACTIONS/Table 1: Headache occurs more frequently with VTAMA than vehicle.
Unsupported Statements
VTAMA is a first-in-class, investigational molecule.
Not supported by any provided label text (absent in supplied sections).
The AhR pathway is involved in inflammation.
No provided label statement linking AhR pathway to inflammation.
By activating AhR, tapinarof modulates inflammatory pathways and keratinocyte changes associated with psoriasis.
The label provided states the specific mechanisms of therapeutic actions are unknown (12.1); no provided text supports downstream inflammatory/keratinocyte modulation claims.
Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company, developed VTAMA.
Not supported by any provided label text (absent in supplied sections).
Contradictions
Important Omissions
The evaluation could not confirm label-based contraindications, boxed warnings, warnings/precautions, use in specific populations (e.g., pregnancy/lactation), monitoring, storage/handling, or complete administration cautions because these sections were not provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No contraindications, boxed warnings, or dosing quantities beyond 'apply once daily' were claimed. Main mismatches are mechanistic/supportability issues rather than direct unsafe dosing instructions; however, missing label sections prevent a complete safety alignment check.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Mechanistic and background-development claims are unsupported, and some mechanistic statements conflict with the label’s statement that specific therapeutic mechanisms are unknown.
Suggested Improvement
Remove or qualify unsupported claims not present in the provided label (e.g., 'first-in-class, investigational', AhR inflammation involvement, inflammatory/keratinocyte modulation). Stick to provided label-supported statements: tapinarof as an AhR agonist and that specific therapeutic mechanisms are unknown.